Eli Lilly's Retatrutide Phase 3 Hits 28.7% Weight Loss at 68 Weeks — Stronger Effect in Women
The obesity drug field jumped another step. Eli Lilly’s retatrutide achieved mean 28.7% body weight loss in the TRIUMPH-4 phase 3 trial over 68 weeks at 12mg dose. Meaningfully exceeding semaglutide (15~17%) and tirzepatide (20~22%) in the same category. More striking data: in phase 2, women showed stronger response than men (28.5% vs 19.8% at 8mg, 26.6% vs 21.9% at 12mg).
Retatrutide’s differentiator is triple hormone receptor activity. Semaglutide is GLP-1 only, tirzepatide is GLP-1 + GIP dual, retatrutide is GLP-1 + GIP + glucagon triple. The glucagon addition is central:
- GLP-1 action: appetite suppression + delayed gastric emptying + insulin secretion
- GIP action: enhanced insulin efficiency + fat metabolism + appetite support
- Glucagon action: hepatic fatty acid oxidation + increased energy expenditure + raised basal metabolism
Glucagon is traditionally known as a glucose-raising hormone, but in balanced combination with GLP-1 and GIP, it activates energy expenditure circuits. Mechanism for burning more energy at the same caloric intake.
TRIUMPH-4 Trial
- Subjects: obesity or overweight + knee osteoarthritis patients
- Dose: 12mg subcutaneous weekly
- Duration: 68 weeks
- Result: mean 28.7% weight loss
- Additional: knee osteoarthritis pain relief (joint burden reduction from weight loss)
- NDA submission: Q4 2026 expected
TRIUMPH-1~7 trials running in parallel. TRIUMPH-1 (80 weeks) expected to hit 30%+ weight loss. After NDA passage, expected as the first triple-agonist obesity drug launching in 2027.
Stronger Effect in Women
Phase 2 (NEJM 2023) data showed women with stronger response than men:
- 8mg dose: women 28.5%, men 19.8%
- 12mg dose: women 26.6%, men 21.9%
Reasons unclear but hypothesized:
- Estrogen-GIP signal crossroads: GIP receptors expressed on adipocytes, possibly modulated by estrogen
- Female fat distribution (subcutaneous-dominant): glucagon’s energy expenditure effect may be stronger in subcutaneous fat
- Body weight + hormone interaction: triple action may act more directly on post-menopausal weight gain
Comparative Position
| Drug | Mechanism | Phase 3 Weight Loss | Launch |
|---|---|---|---|
| Semaglutide (Wegovy) | GLP-1 only | 15~17% | 2021 |
| Oral semaglutide (Wegovy pill) | GLP-1 only oral | 16.6% | 2026.1 |
| Tirzepatide (Zepbound) | GLP-1 + GIP | 20~22% | 2023 |
| Retatrutide | GLP-1 + GIP + glucagon | 28.7% (12mg) | 2027 expected |
Side Effect Profile
Similar to existing GLP-1 with some differences:
- Nausea: 43%
- Vomiting: 21%
- Diarrhea: 33%
- Drug discontinuation rate: 9mg 12.2%, 12mg 18.2% (higher than tirzepatide)
- Dysesthesia (sensory disturbance): 21% (12mg) — new side effect signal. Tingling, prickling in hands and feet. Generally mild.
Clinical Implications
Major meaning for women:
- Post-menopausal weight gain: stronger option for 50+ women
- PCOS + insulin resistance + obesity: triple action operates on insulin and androgen circuits
- Co-occurring knee·joint pain: direct osteoarthritis pain relief data from TRIUMPH-4
- Cardiovascular risk + obesity: SELECT was semaglutide data, but retatrutide’s stronger weight loss expects greater cardiovascular protection
Korean Market Entry
US NDA Q4 2026, FDA approval expected 2027. Korean entry expected 2028~2029. Insurance coverage and specialty disease cost reimbursement set at launch. Expected ₩1,000,000+ monthly out-of-pocket.
Matrix Application
Retatrutide alone struggles to maintain effect. SELECT follow-up reported average two-thirds weight regain after GLP-1 discontinuation. Same pattern expected for retatrutide. Matrix essential:
- Protein 1.2–1.6g/kg/day: muscle loss prevention (30–40% of weight loss comes from muscle)
- Resistance training 2–3×/week: muscle·bone protection
- Calcium 1,200mg + vitamin D 4,000 IU: bone density protection
- Intermittent fasting (16:8) + fiber: microbiome + insulin circuit strengthening
- Sleep 7–9 hours + chronic stress management: cortisol avoidance
Retatrutide is a new peak in the obesity drug ladder, but lifelong drug use + simultaneous matrix is decisive. The drug alone is not the answer.